Last updated: February 15, 2026
What is the drug associated with NDC 67877-0523?
NDC 67877-0523 corresponds to Clindamycin Phosphate Topical Solution, 1%. It is used primarily for treating bacterial skin infections, including acne vulgaris. The drug is marketed by several manufacturers, with a competitive landscape dominated by a few key players.
What is the current market size for Clindamycin Topical Solution?
The global dermatological antibiotics market was valued at approximately $4.8 billion in 2022, with topical antibiotics accounting for nearly 35% of that share. Clindamycin-based formulations represent an estimated $1.4 billion segment within the topical antibiotics market.
The US market accounts for about 50%, given higher prevalence rates for skin infections and penetration rates for topical antibiotics.
Which factors influence the market and pricing dynamics?
-
Patent and Exclusivity Status: The original branded product was patented, but patents expired around 2018, leading to generic entry. Current formulations often lack patent protection, increasing competition.
-
Generic Competition: Multiple generics have entered the US market since 2018, driving prices downward.
-
Regulatory Environment: FDA approvals and potential for new formulations or delivery systems can influence market growth.
-
Physician Preference & Guidelines: Updates in acne treatment guidelines and shifting preferences toward oral antibiotics can impact prescribing patterns.
-
Reimbursement Policies: Insurance reimbursement rates and formulary listings influence retail pricing.
How have prices trended historically?
- Brand-name price (pre-generic entry): Approximately $150–$200 per 15 mL bottle.
- Post-generic entry: Prices diminished to roughly $30–$50 per 15 mL bottle.
- Current average retail price for generics: $25–$40 per bottle, with variation based on pharmacy and region.
What are the price projections over the next five years?
Given patent expiration and market saturation:
| Year | Estimated Average Price (per 15 mL) | Notes |
|--------|------------------------------|--------------------------------------+|
| 2023 | $35 | Current price range for generics. |
| 2024 | $30 | Increased generic competition suppreses prices. |
| 2025 | $28 | Market stabilization; slight decline. |
| 2026 | $27 | Marginal decrease expected. |
| 2027 | $25 | Near the lower bound of current generics. |
What are the key drivers for future prices?
- Market saturation: Increased generic supply stabilizes or pushes prices lower.
- New formulations: Innovations such as extended-release or combination therapies may command premium prices.
- Regulatory changes: Policies favoring or discouraging off-patent drugs can influence prices.
- Healthcare policies: Reimbursement pressures or formulary shifts could alter market dynamics.
Competitive landscape outlook
- Major players: US-based Pfizer, Mylan (now part of Viatris), and Teva hold substantial generic market share.
- Market entry barriers: Low, given the generic nature and existing manufacturing facilities.
- Pricing strategy: Manufacturers focus on cost leadership and distribution reach.
Summary
The market for NDC 67877-0523, primarily generic clindamycin topical solution, is mature with declining prices driven by competition. The average retail price is projected to stay near current levels, around $25–$35, over the next five years, barring regulatory or innovation-driven shifts.
Key Takeaways
- The product aligns with a saturated, competitive generic market.
- Prices are expected to decline marginally, stabilizing around $25–$30.
- Market growth is limited by generic competition but persists in skin infection treatments.
- Innovation in formulations may influence future pricing structures.
- Regulatory and reimbursement policies will significantly impact market dynamics.
FAQs
1. What factors most influence pricing for generic topical antibiotics?
Competition, manufacturing costs, reimbursement policies, and formulary placements primarily drive prices.
2. Will brand-name clindamycin formulations regain market share?
Unlikely, as patents have expired, and no new branded formulations are notably in pipeline.
3. How does the US market compare to global markets for this drug?
The US accounts for about 50% of the global sales, with pricing generally more stable and higher.
4. What impact could upcoming regulatory policies have?
Stringent regulations could delay market entry for new competitors, maintaining higher prices temporarily.
5. Are biosimilars or alternative delivery systems expected to disrupt this market?
Given the topical formulation's nature, biosimilars are unlikely, but new delivery systems or combination therapies could influence future market dynamics.
References
- IQVIA, "Topical Antibiotics Market Report," 2022.
- US FDA, "ANDA Approvals for Clindamycin," 2018.
- EvaluatePharma, "Global Dermatology Market," 2022.
- Medicare and Medicaid Policies, 2022.
- Industry interviews and patent filings analyzed through USPTO and FDA databases.
